03:42:55 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



Imagin Medical Inc
Symbol IME
Shares Issued 127,124,738
Close 2018-06-22 C$ 0.245
Market Cap C$ 31,145,561
Recent Sedar Documents

Imagin to pay Kilmer $7,500 (U.S.) for IR services

2018-06-22 16:18 ET - News Release

Mr. Jim Hutchens reports

IMAGIN PROVIDES FURTHER DETAIL ON KILMER LUCAS ENGAGEMENT

Imagin Medical Inc. has provided, in addition to its press release of June 21, 2018, further details regarding its engagement of Kilmer Lucas Inc.

Kilmer Lucas will provide Imagin with select Canadian and U.S. investor relations and strategic advisory services. Employing an outsourced in-house partnership model, Kilmer Lucas designs and executes customized investor relations programs for medical device, drug development, cell therapy, diagnostics and health care services companies.

Kilmer Lucas is an arm's-length third party to Imagin and it does not have any interest, directly or indirectly, in Imagin (or any right or intent to acquire such an interest). Imagin will pay Kilmer Lucas a monthly retainer fee of $7,500 (U.S.) for its services. The agreement between Imagin and Kilmer Lucas has an initial term of 60 days. After the initial term, the agreement will renew automatically for 30-day periods unless terminated by either party. Kilmer Lucas will be paid out of Imagin's immediately available funds.

About Imagin Medical Inc.

Imagin Medical is developing imaging solutions for the early detection of cancer during minimally invasive surgeries. The company believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth-most prevalent in the United States, and the most costly cancer to treat due to a greater-than-50-per-cent recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.